STEVEN I SHERMAN to Cell Differentiation
This is a "connection" page, showing publications STEVEN I SHERMAN has written about Cell Differentiation.
Connection Strength
0.358
-
A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid. 2014 Oct; 24(10):1508-14.
Score: 0.220
-
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan; 26(1):1-133.
Score: 0.060
-
Socioeconomic factors and the presentation, management, and outcome of patients with differentiated thyroid carcinoma. Thyroid. 2002 Nov; 12(11):1009-16.
Score: 0.024
-
Distant Metastases From Childhood Differentiated Thyroid Carcinoma: Clinical Course and Mutational Landscape. J Clin Endocrinol Metab. 2021 03 25; 106(4):e1683-e1697.
Score: 0.022
-
The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence. Thyroid. 2020 10; 30(10):1490-1495.
Score: 0.020
-
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 2011 Apr; 96(4):997-1005.
Score: 0.011